Professional Development in Endocrine Disorders Management

Professionals should expand their knowledge of medication selection, dosing adjustments, and safety in stage 4 and 5 chronic kidney disease (CKD) patients, especially concerning glucose-lowering therapies and insulin.

Staying current with GLP-1 receptor agonists and SGLT2 inhibitors, their renal and cardiovascular benefits, and their use in advanced CKD is crucial. Additionally, understanding strategies for improving medication adherence in older adults and those with cognitive impairment is vital.

Strengthening skills in preventing, recognising, and managing gastrointestinal adverse effects from GLP-1 receptor agonists is necessary for treatment tolerability. Enhanced expertise in insulin initiation, titration, monitoring, and hypoglycaemia prevention, particularly in older adults and patients with renal impairment, is also emphasized.

Deepening understanding of personalized glycaemic targets, deprescribing principles, frailty assessment, and shared decision-making is essential for older adults. Improved knowledge of how ageing, multimorbidity, cognitive decline, and functional status influence endocrine disease management and pharmacotherapy is also a key area.